Markets: CSL's antidote to excitement

The drug developer's chief has sought to dampen expectations for the company's 2014 performance despite continued demand for its products.

If the 2013 financial year was challenging, CSL chief executive Paul Perreault says 2014 will be even worse. The pharmaceutical company reported a 19 per cent increase in net profit to $US1.21 billion in 2013. CSL says 2014 net income growth will more than halve to 10 per cent.

Perreault may be just dampening expectations. But it points to nervousness about the health of the US economy and the uncertain regulatory environment facing many companies in and outside the pharmaceutical sector.

{{content.question}}

{{ twilioFailed ? 'SMS Code Failed to Send…' : 'SMS Code Sent…' }}

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa
Mastercard

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device


Register as a new member

(using a different email)

Related Articles